Oncimmune Holdings has appointed Dr Adam Hill as chief executive, with founder Geoffrey Hamilton-Fairley becoming vice-chairman.

Hill (pictured) steps up to the role having joined Oncimmune from McLaren Applied Technologies earlier this year as chief medical officer, chief scientific officer and executive director. Hill has also led Oncimmune’s R&D team and a strategic review of the company.

Hamilton-Fairley moves into the newly-created role of vice chairman and will assist in developing the new senior leadership team, as well as continuing to support the company on certain key strategic projects.

Oncimmune develops, manufactures and markets personalised immunodiagnostics for the screening, detection, and care of cancer. The company says it focuses on opportunities presented by its proprietary auto-antibody-based platform for individual profiling of cancer-related antigens.

Hill said: “Oncimmune has a strong and proprietary position in immune profiling of cancer, and a compelling pipeline of clinical and commercial phase assets that will help unlock the potential of personalised immunodiagnostics for a broad portfolio of cancer indications.

“As the field of oncology sits on the cusp of dramatically improved cancer survivorship, I look forward to working with the company’s experienced board, and its highly talented executive and scientific teams to take Oncimmune’s immunodiagnostic solutions through clinical development and into the hands of clinicians to improve patient outcomes.”

Hamilton-Fairley added: “It has been a great experience leading Oncimmune from its spin out from Nottingham University and a team of dedicated colleagues and research collaborators who have been working together to transform the treatment of cancer through immunodiagnostics leading to early detection and improved care and outcomes.

“The company is well positioned for an exciting future and it is now time to transition to new leadership who will take our products and technology through clinical development and broad global commercialisation, and Adam has demonstrated that he is the ideal leader to deliver the next phase of Oncimmune’s growth.”